Read the Journal
The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Become a Reviewer
From the Editors
As the Society's official journal, JITC is proud to provide the formal publication of the meeting abstracts. With individual, unique digital object identifiers (DOIs) for each abstract, it is easy to share parti
cular abstracts of interest with others. View the SITC 37th Annual Meeting (SITC 2022) Abstracts here.
JITC's latest Impact Factor of 12.469 was announced in the 2022 Journal Citation Reports (JCR), placing the journal in the top 12% of the oncology and immunology categories. The Impact Factor is a calculation determined on the number of 2021 citations accumulated for JITC manuscripts published in 2019 and 2020. Other valuable journal metrics for JITC - including the SJR and CiteScore - may be found on the journal website.
Together with SITC, the journal recognizes key contributors to the journal and field of cancer immunotherapy, both in leadership and in research.
Annual JITC Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts.
The Pedro J. Romero, MD Service to JITC Award recognizes an individual who has made significant contributions and demonstrated outstanding commitment to the journal.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2022. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author. JITC also offers full waivers for the full APC (100% discount of the APC) where all authors are based in low-income countries (see policy). Requests for waivers must be made prior to submission. For additional information regarding these discounts, as well as institutional arrangements, view the journal's APC policy. Additional questions may be directed to JITCEditor@sitcancer.org.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com